EUCTR2019-003936-21-IT进行中（未招募）1 期
A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study. AMELIORATE (AML Early IntensificatiOn based on peRipheral blAsT clEarance). - AMELIORATE
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS0 个研究点目标入组 172 人开始时间: 2021年6月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients with de novo AML, untreated, newly diagnosed, according to WHO 2016 criteria
- •2.Presence of a mutation of FLT3 gene, either ITD and/or TKD
- •3.Adequate availability of diagnostic biologic material for full cytological, cytogenetic, genetic and immunophenotypic disease characterization according to ELN criteria.
- •4.Presence of morphologically identifiable blasts on peripheral blood at diagnosis
- •5.Presence of a Leukemia-associated aberrant immune-phenotype (LAIP) as assessed by MFC (multiparametric flow cytometry) at diagnosis
- •6.Age between 18 and 65 years, included
- •7.ECOG performance status 0-2 or disease-related reversible ECOG 3 score following adequate supportive care.
- •8.Signed written informed consent according to ICH/EU/GCP and national local laws.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 72
排除标准
- •1.Diagnosis of acute promyelocytic leukemia
- •2.Diagnosis of AML with t(8;21)(q22:q22)/RUNX1-RUNX1T1 and t(16;16)(p13:q22) or inversion of chromosome 16 (16)(p13q22)/CBFB-MYH11; in case of suspicion of CBF-related AML due to morphological and/or immunophenotypic features, specific FISH or molecular testing is strongly recommended in accordance with WHO criteria3,157
- •3.Patients with LVEF less than 45% (by echocardiogram or MUGA)
- •4.Pre-existing, uncontrolled pathology such as heart failure (congestive/ischaemic, acute myocardial infarction within the post 3 months, untreatable arrhythmias, NYHA classes III and IV), sever liver disease with total bilirubin =2,5 x ULN and/or ALT>3 ULN (unless attributable to AML), acute or chronic pancreatitis, kidney function impairment with serum creatinine =2,5 (unless attributable to AML) and severe neuropsychiatric disorder that impairs the patient’s ability to understand and sign the informed consent or to cope with the intended treatment plan. For altered liver, pancreas and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures.
- •4.5.Pre-existing HIV positive serology (i.e. already known before enrolment). The participation to the study will require serology testing for HIV positivity at baseline: in case of HIV positivity or refusal to perform HIV testing, the patient will be considered not eligible.
- •5.6.Uncontrolled bacterial or fungal infections
- •6.7.QTc >470 msec on screening ECG (Fridericia’s formula)
- •7.8.A history of cancer that is not in remission phase following surgery and/or chemotherapy and/or radiotherapy with life expectancy < 1 year.
- •8.9.Pregnancy declared by the patient herself. A pregnancy test is performed at diagnosis and, if applicable, before allogeneic HSCT. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 4 months after the end of treatment.
研究者
相似试验
进行中（未招募）
1 期
To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).Complicated urinary tract infectionEUCTR2017-003772-31-BGIterum Therapeutics International Limited1,381
进行中（未招募）
1 期
To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).Complicated urinary tract infectionEUCTR2017-003772-31-LVIterum Therapeutics International Limited1,381
进行中（未招募）
1 期
To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).Complicated urinary tract infectionEUCTR2017-003772-31-HUIterum Therapeutics International Limited1,156
进行中（未招募）
1 期
To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).Complicated urinary tract infectionEUCTR2017-003772-31-EEIterum Therapeutics International Limited1,156
进行中（未招募）
1 期
To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).Complicated urinary tract infectionEUCTR2017-003772-31-SKIterum Therapeutics International Limited1,381